Last reviewed · How we verify
BPAN Patients
BPAN Patients is a treatment for a rare genetic disorder.
BPAN Patients is a treatment for a rare genetic disorder. Used for Treatment of BPAN (Beta-Propeller Protein-Associated Neurodegeneration).
At a glance
| Generic name | BPAN Patients |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Biologic |
| Therapeutic area | Genetics |
| Phase | Phase 2 |
Mechanism of action
BPAN Patients is being investigated for its potential to treat a rare genetic disorder. The exact mechanism of action is not well understood, but it is thought to target the underlying genetic cause of the disorder.
Approved indications
- Treatment of BPAN (Beta-Propeller Protein-Associated Neurodegeneration)
Common side effects
- Unknown
Key clinical trials
- Protection Response to Cellular Stress in BPAN's Patient Study
- TIRCON International NBIA Registry
- NBIAready: Online Collection of Natural History Patient-reported Outcome Measures
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPAN Patients CI brief — competitive landscape report
- BPAN Patients updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI